Bisoprolol and magnesium medications in arterial hypertension treatment
Abstract
Aim. To investigate therapeutic efficacy of selective beta-1-adrenoblockers combined with magnesium (Mg) medications, in the treatment of arterial hypertension (AH), as well as their role in blood rheology normalization: effects on platelet aggregation activity (APl), red blood cell electrophoretic mobility (RBC EPM), lipid profile, serum and RBC Mg levels.
Material and methods. One hundred patients were examined: 20 normotensives (mean age 53.1±5.8 years), and 80 hypertensives with Stage I-II AH (mean age 51.41±6.3 years). Mg deficit – RBC Mg concentration <1.6 mmol/l – was observed in 32 AH patients (40%; subgroup A). Subgroup B included 48 hypertensive individuals with RBC Mg concentration >1.6 mmol/l. Bisoprolol monotherapy (7.5±0.15 mg/d) lasted for 6 months. In subgroup A, bisoprolol was combined with Mg medication.
Results. By the end of the treatment, there was a decrease of systolic blood pressure (SBP) by 15%, and diastolic blood pressure (DBP) by 21.3% in subgroup A. In subgroup B, SBP declined by 13.3%, DBP – by 16.3%. RBC Mg concentration correlated with SBP and DBP levels. After 6 months of treatment, APl declined by 31.8% and 19% in subgroups A and B, respectively (р<0.05). There was a strong positive correlation between APl and BP level. RBC EPM increased by 19.7% (p<0.05) and 11.1% (p<0.05) in subgroups A and B, respectively. RBC EPM correlated with BP level, RBC Mg concentration, and plasma atherogenity index (AI). AI decreased by 50.6%, due to reduced triglycerides (-15.1%) and low-density lipoprotein cholesterol (-40.9%) levels, and increased high-density lipoprotein cholesterol levels (+30.6%) (p<0.01).
Conclusion. Bisoprolol, combined with Mg medications in AH treatment program, decreased APl, AI, increased RBC EPM, that resulted in SBP and DPB levels normalization.
About the Authors
A. M. Shilov
I.M. Sechenov Moscow Medical Academy, Moscow
Russian Federation
Russian Federation
M. V. Mel’nik
I.M. Sechenov Moscow Medical Academy, Moscow
Russian Federation
Russian Federation
M. V. Mel’nik
I.M. Sechenov Moscow Medical Academy, Moscow
Russian Federation
Russian Federation
References
1. Арабидзе Г.Г. Принципы лечения артериальной гипертонии. Место антагонистов кальция. «Кардиология 99». Тр I международ науч форума 1999; 54-7.
2. Задионченко В.С., Богатырева К.М., Станкевич Т.В. Тромбоцитарно-сосудистый гемостаз и реологические свойства крови при лечении тенололом больных гипертонической болезнью. Кардиология 1993; 3: 40-4.
3. Габриелян Э.С., Акопов С.Э. Клетки крови и кровообращение. Ереван. Айастан 1985; 257-72.
4. Шилов А.М., Мельник М.В. Соколинская И.Ю. и др. Влияние препаратов магния на гемореологические свойства крови при артериальной гипертонии. Лечение и профилактика АГ. «Кардиология 2000». Москва 2000; 233-3.
5. Бюхлер Ф. О некоторых особых аспектах гипотензивного лечения. Труды второго научного форума с международным участием. «Кардиология 2000». Москва 2000; 190-4.
6. Fogari R, Zoppi A, Tettamanti F, et al. β-blocer effects on plasma lipids in antihypertensive therapy. J Cardiovasc Pharmacol 1990; 16(Suppl. 5): 76-80.
7. Верткин А.Л. Конкор (бисопролол) – качественная жизнь кардиологических больных. Труды III Российского научного форума с международным участием. «Кардиология 2001». Москва 1999; 69-74.
8. Mengden Th, Vetter W. The efficacy of bisoprolol in the treatment of hypertension. Rev Contempor Pharmacother 1997; 8: 55-67.
9. Leopold G. Bisoprolol: pharmacokinetic profile. Rev Contempor Pharmacother 1997; 8: 35-8.
10. Hoffler D, Morgenstern HO. Age dependence of therapy result and risk in the treatment of arterial hypertension? J Cardiovasc Pharmacol 1990; 16(Suppl. 5): 184-5.
Review
For citations:
Shilov A.M., Mel’nik M.V., Mel’nik M.V. Bisoprolol and magnesium medications in arterial hypertension treatment. Cardiovascular Therapy and Prevention. 2005;4(1):36-41. (In Russ.)
Views:
8586
Email this article 
